Innovative Clinical Trials at University of Minnesota Offer New Hope for Glioblastoma Patients
The University of Minnesota is conducting groundbreaking clinical trials for glioblastoma, an aggressive brain cancer, utilizing less invasive laser treatments, engineered viruses, and a drug that aids in tumor identification. These trials aim to directly target cancer cells, offering patients like Brian Braun a quicker recovery and improved quality of life. With glioblastoma affecting an estimated 24,000 people annually, these advancements represent a significant step forward in brain cancer treatment.
Perampanel for Seizure Prevention Post-Craniotomy: A Randomized Trial
• A multi-center, randomized trial is underway in Japan to evaluate perampanel's efficacy in preventing early seizures after craniotomy for brain tumors.
• The trial includes patients aged 18-80 undergoing craniotomy for supratentorial brain tumors and assesses seizure incidence within 28 days post-surgery.
• Patients will be randomized to receive perampanel or standard care, with comprehensive monitoring for adverse events and adherence to the treatment protocol.
• The study aims to determine if perampanel reduces postoperative seizure incidence, length of hospital stay, and other complications compared to the control group.
CAR-T Therapy Induces Dramatic Regression in Glioblastoma Patients
• A Phase 1 clinical trial of CARv3-TEAM-E T cells showed significant tumor regression in recurrent glioblastoma (GBM) patients after a single treatment.
• One patient experienced near-complete tumor regression, while others showed substantial reductions in tumor size, demonstrating the therapy's potential.
• The CAR-TEAM approach combines CAR-T therapy with bispecific antibodies to target both EGFRvIII and wild-type EGFR, addressing tumor heterogeneity.
• While responses were observed, tumor progression eventually occurred, prompting researchers to explore strategies for extending the durability of the treatment.
© Copyright 2025. All Rights Reserved by MedPath